title: Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction.
abstract: Osteonectin is a phosphoglycoprotein exclusively located in bone and platelet alpha-granules. Human platelet-derived osteonectin is released into plasma after thrombin-induced activation. Recognizing the unique distribution of the osteonectin pool, we first sought to investigate whether osteonectin could serve as a sensitive marker of platelet activity, and identify patients with acute myocardial infarction (AMI). The second objective was to define the effects of thrombolytic therapy in these patients on the plasma concentrations of osteonectin at prespecified time points following attempted reperfusion. Osteonectin levels by ELISA were determined in AMI patients before thrombolysis and at 3, 6, 12, and 24 hours thereafter and compared with 12 healthy controls. At baseline, soluble osteonectin plasma levels were similar between controls (447. 7+/-20.6 ng/ml) and AMI patients (425.7+/-43.3 ng/mL; p=NS). A significant increase of the soluble osteonectin was observed at 3 hours after thrombolysis (519.4+/-26.9 ng/mL; p=0.03), and was followed by a decrease to baseline levels at 6 hours after attempted reperfusion. Contrary to expectations, the plasma osteonectin level in our pilot study was not a sensitive marker distinguishing patients with AMI. The early peak of soluble osteonectin at 3 hours after thrombolytic therapy is most likely not related to coronary thrombolysis per se but rather to the phasic changes of platelet activity during myocardial ischemia-reperfusion. The unquestionable platelet origin of this protein and the lack of elevated plasma levels of this alpha-granule constituent, challenge the postulate of uniform platelet activation in AMI patients.
authors.affiliation: Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA. Heardrug@aol.com
authors.forename: V L
authors.initials: VL
authors.lastname: Serebruany
authors.forename: D
authors.initials: D
authors.lastname: Atar
authors.forename: S R
authors.initials: SR
authors.lastname: Murugesan
authors.forename: S
authors.initials: S
authors.lastname: Jerome
authors.forename: H
authors.initials: H
authors.lastname: Semaan
authors.forename: P A
authors.initials: PA
authors.lastname: Gurbel
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D003328:Coronary Thrombosis / Q000097:blood / Q000150:complications / Q000188:drug therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000209:etiology; D015425:Myocardial Reperfusion / Q000379:methods; D015676:Osteonectin / Q000097:blood* / Q000187:drug effects; D010865:Pilot Projects; D012995:Solubility; D013997:Time Factors
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents; D015676:Osteonectin